Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACAD 
ACADIA Pharmaceuticals Inc (ACAD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/17/2025: ACAD (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
20 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $28.84
1 Year Target Price $28.84
| 7 | Strong Buy |
| 6 | Buy |
| 6 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 42.56% | Avg. Invested days 54 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.52B USD | Price to earnings Ratio 15.71 | 1Y Target Price 28.84 |
Price to earnings Ratio 15.71 | 1Y Target Price 28.84 | ||
Volume (30-day avg) 20 | Beta 0.75 | 52 Weeks Range 13.40 - 26.65 | Updated Date 10/17/2025 |
52 Weeks Range 13.40 - 26.65 | Updated Date 10/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 21.8% | Operating Margin (TTM) 12.24% |
Management Effectiveness
Return on Assets (TTM) 5.28% | Return on Equity (TTM) 33.18% |
Valuation
Trailing PE 15.71 | Forward PE 20.75 | Enterprise Value 2901365263 | Price to Sales(TTM) 3.46 |
Enterprise Value 2901365263 | Price to Sales(TTM) 3.46 | ||
Enterprise Value to Revenue 2.85 | Enterprise Value to EBITDA 27.91 | Shares Outstanding 168712220 | Shares Floating 115866491 |
Shares Outstanding 168712220 | Shares Floating 115866491 | ||
Percent Insiders 0.56 | Percent Institutions 101.52 |
Upturn AI SWOT
ACADIA Pharmaceuticals Inc
Company Overview
History and Background
ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. It is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. A key milestone was the FDA approval of NUPLAZID for Parkinson's disease psychosis in 2016.
Core Business Areas
- Neurology: Focuses on the development and commercialization of therapies for neurological disorders, including Parkinson's disease psychosis and Rett syndrome. This segment derives its revenue primarily from sales of NUPLAZID and DAYBUE.
- Other: Explores additional pipeline products and future therapeutic areas within central nervous system disorders. Focus is on research and development.
Leadership and Structure
The CEO is Steve Davis. ACADIA has a typical corporate structure with departments for R&D, commercial operations, finance, and legal.
Top Products and Market Share
Key Offerings
- NUPLAZID (pimavanserin): NUPLAZID is approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It holds a significant market share in this indication, estimated at around 70%. Key competitors include off-label use of antipsychotics like quetiapine (Seroquel) and clozapine. Revenue from NUPLAZID sales represents a substantial portion of ACADIA's overall revenue. NUPLAZID faces competition from generic antipsychotics although it is a unique treatment for Parkinson's disease psychosis.
- DAYBUE (trofinetide): DAYBUE is approved for the treatment of Rett syndrome in adult and pediatric patients 2 years of age and older. It is the first and only FDA-approved treatment for Rett syndrome. As a novel therapy for a specific condition with few or no alternatives, DAYBUE is gaining market traction. There are currently no directly competing FDA-approved products.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the neurosciences sector, is driven by innovation and unmet medical needs. Key trends include the development of targeted therapies, increasing regulatory scrutiny, and rising drug development costs.
Positioning
ACADIA is positioned as a leader in developing and commercializing innovative therapies for central nervous system disorders. Their competitive advantage lies in their focus on specific patient populations with limited treatment options.
Total Addressable Market (TAM)
The TAM for Parkinson's disease psychosis and Rett syndrome combined is estimated to be several billion dollars. ACADIA is positioned to capture a significant portion of this market with NUPLAZID and DAYBUE respectively.
Upturn SWOT Analysis
Strengths
- FDA-approved products (NUPLAZID and DAYBUE)
- Strong market share in Parkinson's disease psychosis
- First and only FDA approved product for Rett Syndrome.
- Focus on specific, unmet medical needs
- Experienced management team
Weaknesses
- Reliance on a limited number of products
- Potential for generic competition to NUPLAZID in the future
- High R&D expenses
- Commercialization risk for new products
Opportunities
- Expansion of existing product indications
- Development of new therapies for other CNS disorders
- Strategic partnerships and acquisitions
- Geographic expansion
Threats
- Regulatory hurdles and delays
- Competition from other pharmaceutical companies
- Pricing pressures
- Clinical trial failures
- Patent expirations
Competitors and Market Share
Key Competitors
- TEVA
- ITCI
- LLY
Competitive Landscape
ACADIA has a competitive advantage in the treatment of Parkinson's disease psychosis with NUPLAZID. With Daybue, Acadia is the only treatment available for Rett Syndrome. Competitors are developing therapies for related conditions, but Acadia's established market presence and innovative products give it an edge.
Growth Trajectory and Initiatives
Historical Growth: ACADIA's historical growth has been driven by the commercial success of NUPLAZID. The launch of DAYBUE is expected to contribute to future growth.
Future Projections: Analyst projections suggest continued revenue growth for ACADIA, driven by NUPLAZID and DAYBUE. The success of pipeline products will also influence future growth.
Recent Initiatives: Recent initiatives include the commercial launch of DAYBUE, ongoing clinical trials for pipeline products, and exploration of strategic partnerships.
Summary
ACADIA Pharmaceuticals shows potential, given its focus on unmet neurological needs and two FDA-approved drugs. Nuplazid generates most of the revenue, while Daybue offers growth prospects. The company's challenges include high R&D costs and reliance on few products, so it must be strategic about expanding indications, product pipelines, and managing regulatory risks to solidify its market position and ensure financial stability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q)
- Analyst Reports
- Press Releases
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial professional. Market share information is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ACADIA Pharmaceuticals Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2004-05-27 | CEO & Director Ms. Catherine E. Owen Adams | ||
Sector Healthcare | Industry Biotechnology | Full time employees 653 | Website https://www.acadia.com |
Full time employees 653 | Website https://www.acadia.com | ||
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.